Your browser is no longer supported. Please, upgrade your browser.
MediWound Ltd.
Index- P/E- EPS (ttm)-0.34 Insider Own42.96% Shs Outstand27.22M Perf Week-4.85%
Market Cap141.78M Forward P/E- EPS next Y-0.54 Insider Trans0.00% Shs Float15.57M Perf Month-9.25%
Income-9.30M PEG- EPS next Q-0.11 Inst Own19.50% Short Float0.52% Perf Quarter29.77%
Sales21.80M P/S6.50 EPS this Y-548.40% Inst Trans4.29% Short Ratio0.51 Perf Half Y36.36%
Book/sh0.27 P/B18.89 EPS next Y-125.00% ROA-26.50% Target Price7.67 Perf Year209.09%
Cash/sh0.77 P/C6.63 EPS next 5Y- ROE-94.50% 52W Range1.61 - 6.07 Perf YTD37.84%
Dividend- P/FCF- EPS past 5Y19.30% ROI-92.10% 52W High-15.98% Beta1.58
Dividend %- Quick Ratio3.00 Sales past 5Y105.00% Gross Margin34.70% 52W Low216.77% ATR0.37
Employees75 Current Ratio3.20 Sales Q/Q24.10% Oper. Margin-40.90% RSI (14)46.19 Volatility4.82% 6.78%
OptionableNo Debt/Eq0.32 EPS Q/Q51.00% Profit Margin-42.30% Rel Volume0.52 Prev Close5.26
ShortableYes LT Debt/Eq0.23 EarningsFeb 25 BMO Payout- Avg Volume158.29K Price5.10
Recom1.70 SMA20-3.66% SMA50-5.36% SMA20022.16% Volume85,208 Change-3.04%
Sep-23-20Initiated BTIG Research Buy $6
Nov-28-16Initiated Aegis Capital Buy $11
Aug-17-16Initiated Wells Fargo Outperform
Apr-16-14Initiated Oppenheimer Outperform $25
Apr-02-21 03:54AM  
Mar-24-21 04:05PM  
Feb-25-21 04:01PM  
Feb-22-21 06:30AM  
Feb-16-21 04:05PM  
Feb-10-21 04:15PM  
Feb-01-21 04:02AM  
Jan-11-21 07:00AM  
Jan-05-21 07:00AM  
Dec-21-20 07:30AM  
Dec-15-20 07:52AM  
Dec-14-20 04:15PM  
Nov-30-20 02:18AM  
Nov-10-20 08:45AM  
Nov-03-20 12:30PM  
Nov-02-20 04:01PM  
Oct-28-20 07:00AM  
Oct-14-20 08:00AM  
Sep-29-20 10:17AM  
Sep-16-20 07:30AM  
Sep-15-20 12:14PM  
Sep-03-20 09:00AM  
Aug-25-20 07:00AM  
Aug-06-20 12:35PM  
Jul-31-20 02:53PM  
Jul-30-20 12:33PM  
Jul-28-20 08:00AM  
Jul-14-20 08:54AM  
Jun-30-20 07:00AM  
May-27-20 10:29AM  
May-26-20 08:16AM  
May-20-20 08:15AM  
May-13-20 08:00AM  
May-12-20 12:30PM  
May-04-20 07:30AM  
May-02-20 10:18AM  
Apr-27-20 07:00AM  
Mar-30-20 07:30AM  
Mar-10-20 03:17AM  
Mar-03-20 06:00AM  
Feb-28-20 04:18PM  
Feb-25-20 08:45AM  
Feb-18-20 08:00AM  
Jan-13-20 08:00AM  
Jan-06-20 06:30AM  
Jan-03-20 11:29AM  
Jan-02-20 07:30AM  
Dec-06-19 12:00AM  
Dec-03-19 07:30AM  
Nov-14-19 08:25AM  
Nov-07-19 10:30AM  
Nov-06-19 08:00AM  
Nov-05-19 10:31AM  
Oct-02-19 07:30AM  
Sep-03-19 08:00AM  
Aug-21-19 03:14PM  
Aug-14-19 07:02AM  
Aug-13-19 08:35AM  
Aug-06-19 08:00AM  
Jul-30-19 10:38AM  
Jul-22-19 07:00AM  
Jul-16-19 08:00AM  
Jun-21-19 12:53PM  
Jun-12-19 11:02PM  
Jun-11-19 07:30AM  
Jun-04-19 07:30AM  
May-29-19 07:30AM  
May-21-19 08:25AM  
May-14-19 08:00AM  
May-08-19 06:24AM  
May-07-19 02:00AM  
May-02-19 10:33AM  
Mar-28-19 12:23PM  
Mar-26-19 08:00AM  
Mar-25-19 07:26AM  
Mar-18-19 08:00AM  
Mar-12-19 07:00AM  
Mar-11-19 10:30AM  
Feb-12-19 01:40PM  
Jan-22-19 09:25AM  
Jan-07-19 07:00AM  
Dec-19-18 04:38PM  
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MWPC005, a topically applied biological drug candidate that is in Phase I/II clinical trial for the treatment of non-melanoma skin cancers; and MWPC003 for connective tissue disorders. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.